ETFS Holding Antares Pharma, Inc.

 
Stock Quotes for Antares Pharma, Inc. top ^
  • Industry: Medical Instruments & Supplies
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Distressed
Sign-up for atrs investment picks
  • Industry: Medical Instruments & Supplies
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Distressed
Sign-up for atrs investment picks

 
News Articles for Antares Pharma, Inc. top ^
2015/1/8
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P.
Sign-up for Antares Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
2015/1/13
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received written recommendations from the U.S. Food and Drug Administration (FDA) related to its clinical development program for QuickShot ® Testosterone (QS T). The recommendations received were in response to various clinical, CMC (Chemistry, Manufacturing and Controls) and user study submissions made by the Company through November 2014.
Sign-up for Antares Pharma Announces Update to QuickShot® Testosterone Program investment picks
2015/1/26
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the Abbreviated New Drug Application (ANDA) for Sumatriptan Injection USP for the acute treatment of migraine.
Sign-up for Antares Pharma Provides Regulatory Update on Sumatriptan Injection USP investment picks
2015/2/23
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Eamonn P.
Sign-up for Antares Pharma to Present at the Cowen and Company 35Th Annual Healthcare Conference investment picks
2015/2/18
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P.
Sign-up for Antares Pharma to Present at the 2015 RBC Capital Markets’ Global Healthcare Conference investment picks
2015/2/25
Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive top-line pharmacokinetic results that showed that the primary endpoint was achieved in the Company’s ongoing, multi-center, phase 3 clinical study (QST-13-003) evaluating the efficacy and safety of testosterone enanthate administered once-weekly by subcutaneous injection using the QuickShot ® auto injector in testosterone deficient adult males.
Sign-up for Antares Pharma Announces Positive Top-Line Pharmacokinetic Results from the QuickShot® Phase 3 Study in Testosterone Deficient Men investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
ETFS Holding Antares Pharma, Inc.
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ETFS Holding ANSYS, Inc.  |  Next: ETFS Holding Antofagasta PLC